Microbot Medical To Present Full U.S. LIBERTY System Release at Needham Conference
Microbot Medical commenced full U.S. market release of its FDA-cleared LIBERTY Endovascular Robotic System this week following a limited release at the SIR Annual Scientific Meeting. CEO Harel Gadot will present commercial achievements and strategic growth plans at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026.
1. Full Market Release of LIBERTY System
Microbot Medical completed its limited market release of the LIBERTY Endovascular Robotic System at the SIR Annual Scientific Meeting and this week commenced its full market release across the United States, marking broad commercial availability of the FDA-cleared, single-use robotic platform.
2. Upcoming Needham Conference Presentation
On April 15, 2026 at 10:15 a.m. ET, CEO Harel Gadot and senior executives will present at the 25th Annual Needham Virtual Healthcare Conference, detailing recent commercial achievements, strategic market positioning and growth opportunities targeting physician radiation risks, physical strain and staffing challenges.
3. System Design and Clinical Benefits
The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures, engineered for precise vascular navigation to reduce operator radiation exposure and physical fatigue during interventions.
4. Investor Engagement Campaign
Alongside the webcast, Microbot Medical’s team is conducting one-on-one meetings with healthcare-focused institutional investors, with scheduling available through Needham sales representatives or the company’s investor relations email.